Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 144-152 |
| Number of pages | 9 |
| Journal | Cancer Imaging |
| Volume | 10 |
| Issue number | 1 |
| Publication status | Published - 6 Jul 2010 |
Fingerprint
Keywords
- assessing therapy response
- breast cancer
- diagnosis
- identification of recurrence
- pharmacological biomarker
- positron emission tomography
- predictive biomarker
- staging
- surrogate response biomarker
- tumour subtyping
Cite this
Opportunities for PET to deliver clinical benefit in cancer : breast cancer as a paradigm. / Fleming, Ian N; Gilbert, Fiona J; Miles, Ken A; Cameron, David.
In: Cancer Imaging, Vol. 10, No. 1, 06.07.2010, p. 144-152.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Opportunities for PET to deliver clinical benefit in cancer
T2 - breast cancer as a paradigm
AU - Fleming, Ian N
AU - Gilbert, Fiona J
AU - Miles, Ken A
AU - Cameron, David
PY - 2010/7/6
Y1 - 2010/7/6
N2 - The glucose analogue fluorodeoxyglucose (FDG) has demonstrated enhanced uptake in the majority of tumours as a result of increased uptake and fixation by phosphorylation. It is the most widely used radiotracer in positron emission tomography (PET), being used in >90% of scans, and is useful for diagnosis, staging and detection of residual/recurrent cancer. However, there are limits to the utility of FDG, particularly in certain tumour types. The development of new radiotracers to study molecular processes such as proliferation, apoptosis, angiogenesis and hypoxia will complement FDG by providing additional information on the cell biology of tumours. The aim of this paper is to consider how the availability of new tracers, or new applications for existing PET/CT technologies, could deliver clinical benefit in cancer, using breast cancer as a paradigm.
AB - The glucose analogue fluorodeoxyglucose (FDG) has demonstrated enhanced uptake in the majority of tumours as a result of increased uptake and fixation by phosphorylation. It is the most widely used radiotracer in positron emission tomography (PET), being used in >90% of scans, and is useful for diagnosis, staging and detection of residual/recurrent cancer. However, there are limits to the utility of FDG, particularly in certain tumour types. The development of new radiotracers to study molecular processes such as proliferation, apoptosis, angiogenesis and hypoxia will complement FDG by providing additional information on the cell biology of tumours. The aim of this paper is to consider how the availability of new tracers, or new applications for existing PET/CT technologies, could deliver clinical benefit in cancer, using breast cancer as a paradigm.
KW - assessing therapy response
KW - breast cancer
KW - diagnosis
KW - identification of recurrence
KW - pharmacological biomarker
KW - positron emission tomography
KW - predictive biomarker
KW - staging
KW - surrogate response biomarker
KW - tumour subtyping
M3 - Article
VL - 10
SP - 144
EP - 152
JO - Cancer Imaging
JF - Cancer Imaging
SN - 1470-7330
IS - 1
ER -